Cellectar Biosciences Partners With City Of Hope Cancer Center To Focus On Clinical Development Of Cellectar's Lead Radioconjugate Asset, Iopofosine I 131, In Mycosis Fungoides; Initiation Is Planned For Late 2024 Or Early 2025
Portfolio Pulse from Benzinga Newsdesk
Cellectar Biosciences has partnered with City of Hope Cancer Center to focus on the clinical development of its lead radioconjugate asset, Iopofosine I 131, for treating Mycosis Fungoides. The initiation of this development is planned for late 2024 or early 2025.
May 29, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectar Biosciences has entered into a partnership with City of Hope Cancer Center to develop its lead radioconjugate asset, Iopofosine I 131, for Mycosis Fungoides. Clinical trials are expected to begin in late 2024 or early 2025.
The partnership with a reputable institution like City of Hope Cancer Center is likely to boost investor confidence in Cellectar Biosciences. The focus on developing a lead asset for a specific cancer type indicates a clear strategic direction, which is positive for the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100